These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 25881012)

  • 1. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.
    Liu L; Yu H; Huang X; Tan H; Li S; Luo Y; Zhang L; Jiang S; Jia H; Xiong Y; Zhang R; Huang Y; Chu CC; Tian W
    BMC Cancer; 2015 Mar; 15():170. PubMed ID: 25881012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
    Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
    Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.
    Akatsu Y; Yoshimatsu Y; Tomizawa T; Takahashi K; Katsura A; Miyazono K; Watabe T
    Cancer Sci; 2017 Jan; 108(1):151-155. PubMed ID: 28133920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys.
    Ren X; Li J; Xu X; Wang C; Cheng Y
    Exp Eye Res; 2016 Apr; 145():352-358. PubMed ID: 26919788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin Fc domain fusion to apolipoprotein(a) kringle V significantly prolongs plasma half-life without affecting its anti-angiogenic activity.
    Yu HK; Lee HJ; Ahn JH; Lim IH; Moon JH; Yoon Y; Yi LS; Kim SJ; Kim JS
    Protein Eng Des Sel; 2013 Jun; 26(6):425-32. PubMed ID: 23571426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.
    Tseng FJ; Chen YC; Lin YL; Tsai NM; Lee RP; Chung YS; Chen CH; Liu YK; Huang YS; Hwang CH; Lai YK; Liao KW
    Cancer Biol Ther; 2010 Nov; 10(9):865-73. PubMed ID: 20818186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis.
    Kim YJ; Bae J; Shin TH; Kang SH; Jeong M; Han Y; Park JH; Kim SK; Kim YS
    J Control Release; 2015 Oct; 216():56-68. PubMed ID: 26260451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2.
    Jiang J; Xu K; Wang L; Xin W; Zhao G; Huang M; Li S; Luan X; Fang J
    Eur J Pharm Sci; 2018 Aug; 121():251-259. PubMed ID: 29715501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.
    Yu DC; Lee JS; Yoo JY; Shin H; Deng H; Wei Y; Yun CO
    Mol Ther; 2012 May; 20(5):938-47. PubMed ID: 22273580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
    Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
    Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models.
    Cicatiello V; Apicella I; Tudisco L; Tarallo V; Formisano L; Sandomenico A; Kim Y; Bastos-Carvalho A; Orlandi A; Ambati J; Ruvo M; Bianco R; De Falco S
    Oncotarget; 2015 Apr; 6(12):10563-76. PubMed ID: 25868854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
    Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
    Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel glycosylated VEGF decoy receptor fusion protein, VEGF-Grab, efficiently suppresses tumor angiogenesis and progression.
    Lee JE; Kim C; Yang H; Park I; Oh N; Hua S; Jeong H; An HJ; Kim SC; Lee GM; Koh GY; Kim HM
    Mol Cancer Ther; 2015 Feb; 14(2):470-9. PubMed ID: 25534360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
    Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
    Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
    Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
    Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments.
    Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Woisetschläger M; Sun H; Rüker F
    Protein Eng Des Sel; 2017 Sep; 30(9):657-671. PubMed ID: 28981753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.